Bio-Path Q3 net loss widens to $3.5M; begins Phase 1/1b for BP1002 in AML

BIO-PATH HOLDINGS, INC.

2022-Q3 EPS reported -$1.38

Net loss $3.5M ($0.49/share) vs $2.1M ($0.29/share) in Q3 2021.
R&D expense doubled to $2.4M on manufacturing costs and BP1001-A trial startup.
Cash $13.7M at Sep 30, 2022, down from $23.8M at Dec 31, 2021; YTD ops burn $10.1M.
First patient dosed in Phase 1/1b study of BP1002 for refractory/relapsed AML.
Closed $2.0M registered direct offering of 800k shares at $2.50 each, with warrants.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-PATH HOLDINGS, INC. reported three months ended September 30, 2022 results: net income Net loss of $3.5 million, EPS $0.49 per share.

Period: three months ended September 30, 2022
Net income: Net loss of $3.5 million
EPS: $0.49 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022, compared to a net loss of $2.1 million, or $0.29 per share, for the three months ended September 30, 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-017917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.